{
  "ticker": "LLY",
  "target_date": "2025-01-17",
  "actual_date": "2025-01-17",
  "collected_at": "2025-12-08T11:17:29.624381",
  "price": {
    "open": 742.29,
    "high": 749.69,
    "low": 719.64,
    "close": 720.3469848632812,
    "volume": 5560100,
    "change_1d_pct": -4.21,
    "change_7d_pct": -6.15,
    "change_30d_pct": -10.77
  },
  "technicals": {
    "rsi_14": 31.34,
    "sma_20": 767.43,
    "sma_50": 776.59,
    "macd": -11.252,
    "macd_signal": -7.353,
    "macd_histogram": -3.898,
    "bb_upper": 807.1,
    "bb_lower": 727.76,
    "price_vs_sma20_pct": -6.14,
    "price_vs_sma50_pct": -7.24,
    "volume_ratio": 1.45
  },
  "fundamentals": {
    "market_cap": 889509249024,
    "pe_ratio": 48.615875,
    "forward_pe": 43.788616,
    "price_to_book": 37.35881,
    "price_to_sales": 14.9699135,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.77,
    "pct_from_52w_low": 59.07
  },
  "macro": {
    "spy": {
      "price": 592.39,
      "change_1d_pct": 1.0,
      "change_7d_pct": 1.37
    },
    "vix": {
      "level": 15.97,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.61
    },
    "dollar_index": {
      "level": 109.35
    },
    "gold": {
      "price": 2744.3
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon",
      "source": "SeekingAlpha",
      "datetime": 1737136997,
      "summary": "MoonLake Immunotherapeutics is set to release results from both the phase 3 VELA-1 and VELA-2 studies in mid-2025. Click here to read why MLTX is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=99ba917a1d81d5a66e2bd5f86068fccb4f00de175a45a15b629998787f2025a3"
    },
    {
      "headline": "Here's How Donald Trump Could Shake Up Health Care \u2014 And Biotech Stocks",
      "source": "DowJones",
      "datetime": 1737122146,
      "summary": "Here's How Donald Trump Could Shake Up Health Care \u2014 And Biotech Stocks",
      "url": "https://finnhub.io/api/news?id=2f63261d896407b0b28b62ebe819868ef49cb4ee09403d55be369318e2f50d37"
    },
    {
      "headline": "Medicare Will Pay Less for Ozempic and Wegovy in 2027. The Price-Negotiation List Is Out.",
      "source": "MarketWatch",
      "datetime": 1737111960,
      "summary": "Medicare Will Pay Less for Ozempic and Wegovy in 2027. The Price-Negotiation List Is Out.",
      "url": "https://finnhub.io/api/news?id=328bc6fffa4a6f7b3aec17beb326850f0b0b2aeaf512fc90c051feec96e90632"
    },
    {
      "headline": "Lilly IBD biologic receives expanded US approval",
      "source": "Finnhub",
      "datetime": 1737025272,
      "summary": "The US Food and Drug Administration has approved Omvoh \u00ae for moderately to severely active Crohn\u2019s disease in US adults. The biologic was authorised in the US as a first-in-class therapy for...",
      "url": "https://finnhub.io/api/news?id=3dc34b475d502b177224e6be9d758c2ab9b198acf40dadadde336fb5dad7785f"
    },
    {
      "headline": "Finally An Attractive Entry Point Into Novo Nordisk",
      "source": "SeekingAlpha",
      "datetime": 1737014178,
      "summary": "Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%.",
      "url": "https://finnhub.io/api/news?id=96dbaef748aa42cc8684a23308bf03ddf2d06ea3f4e4861125d645555fac6eb5"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "8-K",
      "date": "2025-01-14",
      "description": "lly-20250114.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000005/lly-20250114.htm"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470584.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000291/xslF345X05/wk-form4_1734470584.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470498.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000289/xslF345X05/wk-form4_1734470498.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470366.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000287/xslF345X05/wk-form4_1734470366.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470270.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000285/xslF345X05/wk-form4_1734470270.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}